Days lost due to disability of diclofenac-induced adverse drug reactions
Main Article Content
Keywords
Abstract
Disability Adjusted Life Years (DALY) is a widely used measure to quantify the burden of diseases or illness. DALYs for a disease is calculated as the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the equivalent healthy Years Lost due to Disability (YLD). The only difference from the YLD and Days Lost due to Disability (DLD) calculation is that instead of considering the duration of Adverse Drug Reaction (ADR) in years, it is calculated in days.
Objective: DLD was measured for diclofenac tablets to prepare the ADR profile.
Methods: The study was done on the patients (18-65 years old) attending the community pharmacy at Kasaragod district, South India, with prescription of diclofenac tablets. Patients reported ADRs on their next visit to the pharmacy or they had called to the provided phone number and reported it. Disability Weight (DW) was calculated in an analogue scale from 0-1. Zero represent complete health and 1 represent death or equivalent condition. DW was multiplied with occurrence and duration of ADRs in days.
Results: About 943 patients received diclofenac tablets in 1000 prescriptions were successfully followed up for possible, probable and definite ADRs. A total of 561 reactions reported in 2010 for diclofenac tablet in the study population. There were 34 different types of ADRs under 12 physiological systems/organs. Most common reactions were on gastrointestinal (GI) system (48%), followed by skin (14%), Central Nervous System (10%), renal (7%), and cardiovascular (7%). Abdominal pain, cramps or flatulence was the highest occurring GI ADR (107), followed by 43 rashes, 42 nausea/vomiting, 37 indigestion, 34 peptic ulcers, 31 edema etc. DLD for peptic ulcer was considerably high (0.078) per 1000 of the study population on diclofenac. The most damaging ADR were peptic ulcer with or without perforation, followed by rash 0.036 DLD and edema 0.027 DLD. There was considerable DLD by acute renal failure (0.012) Steven-Johnson syndrom (0.013) even though few cases were reported.
Conclusion: Diclofenac has a complex adverse drug profile. Around 34 types of reactions were reported. Diclofenac was widely prescribed because of the experiential belief of comparative safety with other NSAIDs. The study shows the importance of pharmacovigilance even on the most prescribed medicine. Most disabling ADR for the study population was peptic ulcer with or without perforation. YLD or DLD are useful measures of calculating disability caused by ADRs. Future studies could focus on improving the usefulness & precision of DLD.
Keywords: Diclofenac. Drug Toxicity. Quality-Adjusted Life Years. Disability Evaluation. India.
References
2. Gor AP, Saksena M, Adverse drug reactions of nonsteroidal anti-inflammatory drugs in orthopedic patients. J Pharmacol Pharmacother. 2011;2(1):26-29.
3. Aagaard L, Hansen EH.Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIS And NSAIDs. BMC Clin Pharmacol. 2009;9:4.
4. Fendrick AM, Greenberg BP. A Review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis, Osteopath Med Prim Care. 2009;3:1.
5. Thomas D, Mathew M, Raghavan VC., Risk assessment of non steroidal anti-inflammatory drugs. Available at: http://www.pharmainfo.net/reviews/risk-assessment-non-steroidal-anti-inflammatory-drugs (Accessed on Aug 2011).
6. Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, González-Aveledo L. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs: an update, Pharmaceuticals. 2010;3:10-18.
7. Noel MV, Sushma M, Guido S. Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center. Indian J Pharmacol. 2004;36(5):292-295.
8. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents - a 6 year series from Chandigarh, India. J Postgrad Med. 2001;47(2):95-99.
9. WHO. The global burden of disease: 2004 Update. Geneve: WHO; 2008.
10. WHO. GDB study operations manual final draft, Harvard University; 2009.
11. NHS. NICE, Measuring effectiveness and cost effectiveness: the QALY. Available at: http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp (Accessed on August 2011).
12. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYS) in cost-effectiveness analysis. Health Policy Plan. 2001;16(3):326-331.
13. WHO. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneve: WHO; 2008.
14. National Institute of Cholera and Enteric Diseases, Estimation of the burden of diarrhoeal diseases in India, Kolkata, 2004. Available at: http://www.whoindia.org/LinkFiles/Commision_on_Macroeconomic_and_Health_Bg_P2_Estimation_of_the_burden_of_diarrhoeal_diseases_in_India.pdf
15. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747-1757.
16. Oliveira AF, Valente JG, Leite Ida C, Schramm JM, Azevedo AS, Gadelha AM. Global burden of disease attributable to diabetes mellitus in Brazil. Cad Saude Publica. 2009;25(6):1234-1244.
17. Thomas D, Mathew M, Raghavan VC. Age and gender variation in burden of non-steroidal anti-inflammatory medication induced adverse drug reactions. Safety Science Monitor, 2011;15(3):4. Available at: http://ssmon.chb.kth.se/vol15/issue3/4_Thomas.pdf (Accessed on September 2011).
18. Lopez, A. D, Mathers CD, Ezzati M, Jamison DT, Murray CJL, Eds. Global burden of disease and risk factors. New York: Oxford University Press; 2006. http://files.dcp2.org/pdf/gbd/gbdfm.pdf (Accessed on Dec 2010)
19. Naranjo CA, Busto U, Sellers EM Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A Method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
20. SPNS cooperative agreement evaluation. Karnofsky Rating Scale, Version 6/11/96, 1996.
21. WHO. Global burden of disease database. Available at: http://www.who.int/evidence/bod (Accessed on Dec 2010).
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.